BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 6530890)

  • 1. Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?
    Mertz DP; Eichhorn R
    Klin Wochenschr; 1984 Dec; 62(24):1170-2. PubMed ID: 6530890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].
    Mertz DP; Borner K
    Med Welt; 1983 Sep; 34(36):974-9. PubMed ID: 6633222
    [No Abstract]   [Full Text] [Related]  

  • 3. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.
    Colin JN; Farinotti R; Fredj G; Tod M; Clavel JP; Vignon E; Dietlin F
    Eur J Clin Pharmacol; 1986; 31(1):53-8. PubMed ID: 3780828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy with alllopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances (author's transl)].
    Mertz DP
    Med Klin; 1977 Apr; 72(15):664-8. PubMed ID: 857138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of allopurinol and benzbromarone on the concentration of uridine in plasma.
    Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Yamakita J; Higashino K
    Metabolism; 1997 Dec; 46(12):1473-6. PubMed ID: 9439546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Influence of benzbromarone on the pharmacokinetics and pharmacodynamics of oxipurinol].
    Rüffer C; Zorn G; Henkel E; Mitzkat HJ
    Arzneimittelforschung; 1982; 32(9):1149-52. PubMed ID: 6890841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)].
    Matzkies F; Berg G
    Dtsch Med Wochenschr; 1976 Oct; 101(43):1568-70. PubMed ID: 991731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma oxipurinol concentrations during allopurinol therapy.
    Emmerson BT; Gordon RB; Cross M; Thomson DB
    Br J Rheumatol; 1987 Dec; 26(6):445-9. PubMed ID: 3690140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of urate-lowering therapies on renal handling of uric acid.
    Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
    Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
    Reinders MK; van Roon EN; Houtman PM; Brouwers JR; Jansen TL
    Clin Rheumatol; 2007 Sep; 26(9):1459-65. PubMed ID: 17308859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benzbromarone therapy in hyperuricaemia; comparison with allopurinol and probenecid.
    Schepers GW
    J Int Med Res; 1981; 9(6):511-5. PubMed ID: 7033016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uricosuric medications for chronic gout.
    Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
    Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
    Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
    Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
    Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
    Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The uric acid-lowering action of benzbromarone effervescent granules and allopurinol. Comparative studies (author's transl)].
    Mertz DP
    MMW Munch Med Wochenschr; 1978 Oct; 120(42):1387-90. PubMed ID: 101792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout.
    Müller FO; Schall R; Groenewoud G; Hundt HK; van der Merwe JC; van Dyk M
    Eur J Clin Pharmacol; 1993; 44(1):69-72. PubMed ID: 8436158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study].
    Arntz HR; Dreykluft HR; Leonhardt H
    Fortschr Med; 1979 Jul; 97(27):1212-4. PubMed ID: 457017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current therapy: combined drug therapy of hyperuricemia, gout and alcohol induced fatty liver].
    Mertz DP
    Fortschr Med; 1983 May; 101(18):851-3. PubMed ID: 6862346
    [No Abstract]   [Full Text] [Related]  

  • 20. [Allomaron in hyperuricemia and gout].
    Barsom S
    ZFA (Stuttgart); 1979 Aug; 55(24):1336-40. PubMed ID: 539082
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.